{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "2", "is_major": "Y"}, {"value": "Executive Compensation", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Income Inequality", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Boards of Directors", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "Stock Options and Purchase Plans", "name": "subject", "rank": "7", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "8", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/04/05/upshot/valeant-is-a-reminder-of-the-peril-of-outsize-executive-pay.html", "document_type": "article", "byline": {"person": [{"lastname": "EAVIS", "firstname": "Peter", "role": "reported", "organization": "", "rank": 1}], "original": "By PETER EAVIS"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbWide.jpg", "legacy": {"wide": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "The Upshot", "word_count": "1122", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Compensation based largely on stock price performance probably played a role in the behavior that led to the drug company\u2019s rise and stunning fall.", "pub_date": "2016-04-05T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "The Upshot", "print_headline": "Among Causes of Valeant\u2019s Tumble,  Outsize Executive Pay Shares Blame", "main": "Valeant Is a Reminder of the Peril of Outsize Executive Pay", "content_kicker": "Compensation"}, "print_page": "3", "snippet": "Compensation based largely on stock price performance probably played a role in the behavior that led to the drug company\u2019s rise and stunning fall.", "_id": "57025f2838f0d81980921b09", "slideshow_credits": null, "abstract": "The Upshot; compensation practices likely played role in downfall of Valeant Pharmaceuticals, drug giant that has seen shares fall some 90 percent following revelations about suspect accounting; chief executive J Michael Pearson had acquired shares amounting to 3 percent of company, largely through compensation, giving him strong incentive to see share price rise.  "}